Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Stefan Glück

Stefan Glück

Celgene Corporation, USA

Title: Immuno-Oncology in Breast cancer: early promise?

Biography

Biography: Stefan Glück

Abstract

According to data published in 2013 (Nature), breast cancer (BrCa) is not a disease that harbors high mutational load; nevertheless, it seems that triple negative TN BrCa which by itself is a heterogenous group, may show much higher rates of mutations than hormone receptor (HR) positive BrCa. These mutations in turn might lead to a higher level of neoantigens which are antigenic and can induce an immune response in the host. This concept, has led investigators to design several clinical trials using immune checkpoint inhibitors (ICI) in early (ECB) and metastatic (MBC) BrCa. Unlike in other cancers, there are no ICI approved in this space yet. Several trials in EBC and MBC using ICI in combination will be reported this year which will hopefully result in advancing therapy and improving patients’ outcomes.